LBA30 Phase III ATALANTE/ov29 trial: Atezolizumab (Atz) versus placebo with platinum-based chemotherapy (Cx) plus bevacizumab (bev) in patients (pts) with platinum-sensitive relapse (PSR) of epithelial ovarian cancer (OC)
Authors:
- J.E. KurtzJKJ.E. Kurtz
- E. Pujade-LauraineEPE. Pujade-Lauraine
- A. OakninAOA. Oaknin
- L. BelinLBL. Belin
- I. TsibulakITI. Tsibulak
- D. CibulaDCD. Cibula
- I.B. VergoteIVI.B. Vergote
- O.S. RosengartenORO.S. Rosengarten
- M.J. RodriguesMRM.J. Rodrigues
- N. de GregorioNGN. de Gregorio
- J. Martinez-GarciaJMJ. Martinez-Garcia
- P. PautierPPP. Pautier
- 13 September 2022
- journal article
- abstracts
- Published by Elsevier in Annals of Oncology
- Vol. 33 (7) , S1397